NAPiC DMC Safety report

Inge Christoffer Olsen, PhD

25 January, 2023

Introduction

This is the safety report for the Data Monitoring Committee meeting in the NNAPiC trial. The data are based on an export from the Viedoc electronic data capture system time stamped "_20230125_071722". There are totally 363 patients in the database. Of these 10 are confirmed excluded from the safety set, and 111 were not assessed or quality checked at the time of the proposed interim analysis.

Note that not all events have been coded yet, so there are some inconsistencies in the reporting.

All patients except known exclusions

First we report on the total number of subjects except those who we know are excluded. There are 353 in this dataset with 177 in the placebo arm and 176 in the amoxicillin arm.

AE Summary

Table 1: Summary of Adverse Events

Parameter	Placebo (N=177)	Amoxicillin (N=176)
Number of AEs	[207] 101 (57.1%)	[156] 86 (48.9%)
Number of patients with any AEs?	101 (57.1%)	86 (48.9%)
Number of patients with one AE	56 (31.6%)	52 (29.5%)
Number of patients with two AE	15 (8.5%)	18 (10.2%)
Number of patients with three or more AEs	30 (16.9%)	16 (9.1%)
Number of SAEs	[5] 5 (2.8%)	[4] 4 (2.3%)
Number of patients with any SAEs?	5 (2.8%)	4 (2.3%)

The numbers are [Number of events] Number of patients (percentage of patients), or Number of patients (percentage of patients)

Table 2: Adverse Events by System Organ Class and Preferred term

System Organ Class	Preferred Term	Placebo (N=177)	Amoxicillin (N=176)
Gastrointestinal disorders	#Total	[94] 57 (32.2%)	[64] 44 (25%)
	Breath odour	[1] 1 (0.6%)	
	Cheilitis	[1] 1 (0.6%)	
	Constipation	[1] 1 (0.6%)	
	Diarrhoea	[42] 38 (21.5%)	[39] 36 (20.5%)
	Gingival pain		[1] 1 (0.6%)
	Haematemesis	[1] 1 (0.6%)	
	Nausea		[2] 2 (1.1%)
	Oral mucosal eruption	[1] 1 (0.6%)	[2] 2 (1.1%)
	Tongue blistering	[1] 1 (0.6%)	
	Vomiting	[46] 31 (17.5%)	[20] 15 (8.5%)
General disorders and administration site conditions	#Total	[7] 6 (3.4%)	[2] 2 (1.1%)
	Gait disturbance	[1] 1 (0.6%)	
	Pyrexia	[6] 5 (2.8%)	[2] 2 (1.1%)
Infections and infestations	#Total	[3] 3 (1.7%)	[9] 9 (5.1%)
	Anal abscess	[1] 1 (0.6%)	
	Ear infection	[1] 1 (0.6%)	
	Fungal infection		[2] 2 (1.1%)
	Gastroenteritis	[1] 1 (0.6%)	
	Gastroenteritis viral		[1] 1 (0.6%)
	Otitis media		[2] 2 (1.1%)
	Respiratory tract infection		[2] 2 (1.1%)
	Rhinovirus infection		[1] 1 (0.6%)
	Viral infection		[1] 1 (0.6%)
Injury, poisoning and procedural complications	#Total	[1] 1 (0.6%)	
	Traumatic tooth displacement	[1] 1 (0.6%)	
Investigations	#Total	[1] 1 (0.6%)	
	Platelet count increased	[1] 1 (0.6%)	
Metabolism and nutrition disorders	#Total	[1] 1 (0.6%)	
	Malnutrition	[1] 1 (0.6%)	
Nervous system disorders	#Total	[1] 1 (0.6%)	
	Tremor	[1] 1 (0.6%)	
Psychiatric disorders	#Total	[1] 1 (0.6%)	
	Insomnia	[1] 1 (0.6%)	
Respiratory, thoracic and mediastinal disorders	#Total	[4] 4 (2.3%)	[1] 1 (0.6%)
	Bronchial obstruction	[1] 1 (0.6%)	
	Dyspnoea	[1] 1 (0.6%)	[1] 1 (0.6%)
	Nasal flaring	[1] 1 (0.6%)	
	Tachypnoea	[1] 1 (0.6%)	
Skin and subcutaneous tissue disorders	#Total	[22] 20 (11.3%)	[25] 22 (12.5%)

System Organ Class	Preferred Term	Placebo (N=177)	Amoxicillin (N=176)
	Dermatitis atopic	[1] 1 (0.6%)	[3] 3 (1.7%)
	Miliaria	[1] 1 (0.6%)	[2] 2 (1.1%)
	Rash	[16] 16 (9%)	[14] 13 (7.4%)
	Rash generalised	[4] 4 (2.3%)	[4] 4 (2.3%)
	Rash papular		[1] 1 (0.6%)
	Urticaria		[1] 1 (0.6%)
Surgical and medical procedures	#Total	[1] 1 (0.6%)	
	Hospitalisation	[1] 1 (0.6%)	

Serious Adverse Events

Table 3: Serious Adverse Events by System Organ Class and Preferred term

System Organ Class	Preferred Term	Placebo (N=177)	Amoxicillin (N=176)
General disorders and administration site conditions	#Total		[1] 1 (0.6%)
	Pyrexia		[1] 1 (0.6%)
Infections and infestations	#Total	[1] 1 (0.6%)	[1] 1 (0.6%)
	Anal abscess	[1] 1 (0.6%)	
	Rhinovirus infection		[1] 1 (0.6%)
Metabolism and nutrition disorders	#Total	[1] 1 (0.6%)	
	Malnutrition	[1] 1 (0.6%)	
Respiratory, thoracic and mediastinal disorders	#Total	[1] 1 (0.6%)	
	Bronchial obstruction	[1] 1 (0.6%)	
Surgical and medical procedures	#Total	[1] 1 (0.6%)	
	Hospitalisation	[1] 1 (0.6%)	

Suspected Unexpected Serious Adverse Reaction

Table 4: Suspected Unexpected Serious Adverse Reaction by System Organ Class and Preferred term

System Organ Class	Preferred Term	Placebo	Amoxicillin
Infections and infestations	#Total	[1] 1 (0.6%)	[1] 1 (0.6%)
	Anal abscess	[1] 1 (0.6%)	
	Rhinovirus infection		[1] 1 (0.6%)

Only monitored patients.

Then we report on those patients who have been monitored. There are 242 in this dataset with 119 in the placebo arm and 123 in the amoxicillin arm.

AE Summary

Table 5: Summary of Adverse Events

Parameter	Placebo (N=119)	Amoxicillin (N=123)
Number of AEs	[166] 79 (66.4%)	[122] 69 (56.1%)
Number of patients with any AEs?	79 (66.4%)	69 (56.1%)
Number of patients with one AE	43 (36.1%)	39 (31.7%)
Number of patients with two AE	12 (10.1%)	17 (13.8%)
Number of patients with three or more AEs	24 (20.2%)	13 (10.6%)
Number of SAEs	[4] 4 (3.4%)	[2] 2 (1.6%)
Number of patients with any SAEs?	4 (3.4%)	2 (1.6%)

The numbers are [Number of events] Number of patients (percentage of patients), or Number of patients (percentage of patients)

Table 6: Adverse Events by System Organ Class and Preferred term

System Organ Class	Preferred Term	Placebo (N=119)	Amoxicillin (N=123)
Gastrointestinal disorders	#Total	[94] 57 (47.9%)	[64] 44 (35.8%)
	Breath odour	[1] 1 (0.8%)	
	Cheilitis	[1] 1 (0.8%)	
	Constipation	[1] 1 (0.8%)	
	Diarrhoea	[42] 38 (31.9%)	[39] 36 (29.3%)
	Gingival pain		[1] 1 (0.8%)
	Haematemesis	[1] 1 (0.8%)	
	Nausea		[2] 2 (1.6%)
	Oral mucosal eruption	[1] 1 (0.8%)	[2] 2 (1.6%)
	Tongue blistering	[1] 1 (0.8%)	
	Vomiting	[46] 31 (26.1%)	[20] 15 (12.2%)
General disorders and administration site conditions	#Total	[7] 6 (5%)	[2] 2 (1.6%)
	Gait disturbance	[1] 1 (0.8%)	
	Pyrexia	[6] 5 (4.2%)	[2] 2 (1.6%)
Infections and infestations	#Total	[3] 3 (2.5%)	[9] 9 (7.3%)
	Anal abscess	[1] 1 (0.8%)	
	Ear infection	[1] 1 (0.8%)	
	Fungal infection		[2] 2 (1.6%)
	Gastroenteritis	[1] 1 (0.8%)	
	Gastroenteritis viral		[1] 1 (0.8%)
	Otitis media		[2] 2 (1.6%)
	Respiratory tract infection		[2] 2 (1.6%)
	Rhinovirus infection		[1] 1 (0.8%)
	Viral infection		[1] 1 (0.8%)
Injury, poisoning and procedural complications	#Total	[1] 1 (0.8%)	

System Organ Class	Preferred Term	Placebo (N=119)	Amoxicillin (N=123)
	Traumatic tooth displacement	[1] 1 (0.8%)	
Investigations	#Total	[1] 1 (0.8%)	
	Platelet count increased	[1] 1 (0.8%)	
Metabolism and nutrition disorders	#Total	[1] 1 (0.8%)	
	Malnutrition	[1] 1 (0.8%)	
Nervous system disorders	#Total	[1] 1 (0.8%)	
	Tremor	[1] 1 (0.8%)	
Psychiatric disorders	#Total	[1] 1 (0.8%)	
	Insomnia	[1] 1 (0.8%)	
Respiratory, thoracic and mediastinal disorders	#Total	[4] 4 (3.4%)	[1] 1 (0.8%)
	Bronchial obstruction	[1] 1 (0.8%)	
	Dyspnoea	[1] 1 (0.8%)	[1] 1 (0.8%)
	Nasal flaring	[1] 1 (0.8%)	
	Tachypnoea	[1] 1 (0.8%)	
Skin and subcutaneous tissue disorders	#Total	[22] 20 (16.8%)	[25] 22 (17.9%)
	Dermatitis atopic	[1] 1 (0.8%)	[3] 3 (2.4%)
	Miliaria	[1] 1 (0.8%)	[2] 2 (1.6%)
	Rash	[16] 16 (13.4%)	[14] 13 (10.6%)
	Rash generalised	[4] 4 (3.4%)	[4] 4 (3.3%)
	Rash papular		[1] 1 (0.8%)
	Urticaria		[1] 1 (0.8%)
Surgical and medical procedures	#Total	[1] 1 (0.8%)	
	Hospitalisation	[1] 1 (0.8%)	

Serious Adverse Events

Table 7: Serious Adverse Events by System Organ Class and Preferred term

System Organ Class	Preferred Term	Placebo (N=119)	Amoxicillin (N=123)
General disorders and administration site conditions	#Total		[1] 1 (0.8%)
	Pyrexia		[1] 1 (0.8%)
Infections and infestations	#Total	[1] 1 (0.8%)	[1] 1 (0.8%)
	Anal abscess	[1] 1 (0.8%)	
	Rhinovirus infection		[1] 1 (0.8%)
Metabolism and nutrition disorders	#Total	[1] 1 (0.8%)	
	Malnutrition	[1] 1 (0.8%)	
Respiratory, thoracic and mediastinal disorders	#Total	[1] 1 (0.8%)	
	Bronchial obstruction	[1] 1 (0.8%)	
Surgical and medical procedures	#Total	[1] 1 (0.8%)	
	Hospitalisation	[1] 1 (0.8%)	

Suspected Unexpected Serious Adverse Reaction

Table 8: Suspected Unexpected Serious Adverse Reaction by System Organ Class and Preferred term

System Organ Class	Preferred Term	Placebo	Amoxicillin
Infections and infestations	#Total	[1] 1 (0.8%)	[1] 1 (0.8%)
	Anal abscess	[1] 1 (0.8%)	
	Rhinovirus infection		[1] 1 (0.8%)

Only non-monitored patients.

Then we report on those patients who have not been monitored. There are 111 in this dataset with 58 in the placebo arm and 53 in the amoxicillin arm.

AE Summary

Table 9: Summary of Adverse Events

Parameter	Placebo (N=58)	Amoxicillin (N=53)
Number of AEs	[41] 22 (37.9%)	[34] 17 (32.1%)
Number of patients with any AEs?	22 (37.9%)	17 (32.1%)
Number of patients with one AE	13 (22.4%)	13 (24.5%)
Number of patients with two AE	3 (5.2%)	1 (1.9%)
Number of patients with three or more AEs	6 (10.3%)	3 (5.7%)
Number of SAEs	[1] 1 (1.7%)	[2] 2 (3.8%)
Number of patients with any SAEs?	1 (1.7%)	2 (3.8%)

The numbers are [Number of events] Number of patients (percentage of patients), or Number of patients (percentage of patients)

Table 10: Adverse Events by System Organ Class and Preferred term

System Organ Class	Preferred Term	Placebo (N=58)	Amoxicillin (N=53)

Serious Adverse Events

Table 11: Serious Adverse Events by System Organ Class and Preferred term

System Organ Class	Preferred Term	Placebo (N=58)	Amoxicillin (N=53)

Suspected Unexpected Serious Adverse Reaction

Table 12: Suspected Unexpected Serious Adverse Reaction by System Organ Class and Preferred term

System Organ Class	Preferred Term	Placebo